Graybug Vision, Inc. (NASDAQ:GRAY) CFO Robert S. Breuil sold 7,283 shares of Graybug Vision stock in a transaction dated Wednesday, September 22nd. The stock was sold at an average price of $3.55, for a total value of $25,854.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
NASDAQ GRAY opened at $3.65 on Friday. The company’s 50 day moving average is $3.95 and its 200-day moving average is $4.70. The firm has a market cap of $77.69 million and a P/E ratio of -0.70. Graybug Vision, Inc. has a 12-month low of $3.43 and a 12-month high of $37.88.
Graybug Vision (NASDAQ:GRAY) last posted its quarterly earnings results on Wednesday, August 11th. The company reported ($0.36) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.11. As a group, equities research analysts expect that Graybug Vision, Inc. will post -1.69 earnings per share for the current fiscal year.
About Graybug Vision
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
Further Reading: How dollar cost averaging works
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.